Growth Metrics

Tandem Diabetes Care (TNDM) Net Cash Flow (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Net Cash Flow readings, the most recent being -$2.6 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 114.33% to -$2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.8 million, a 117.21% increase, with the full-year FY2025 number at $19.8 million, up 117.21% from a year prior.
  • Net Cash Flow hit -$2.6 million in Q4 2025 for Tandem Diabetes Care, down from $27.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $47.7 million in Q4 2022 to a low of -$50.4 million in Q3 2023.
  • Median Net Cash Flow over the past 5 years was $2.8 million (2023), compared with a mean of -$380750.0.
  • The widest YoY moves for Net Cash Flow: up 1051.86% in 2025, down 2680.52% in 2025.
  • Tandem Diabetes Care's Net Cash Flow stood at -$41.3 million in 2021, then skyrocketed by 215.5% to $47.7 million in 2022, then tumbled by 144.41% to -$21.2 million in 2023, then surged by 185.11% to $18.0 million in 2024, then crashed by 114.33% to -$2.6 million in 2025.
  • The last three reported values for Net Cash Flow were -$2.6 million (Q4 2025), $27.2 million (Q3 2025), and $8.9 million (Q2 2025) per Business Quant data.